C29 是一种Toll-like receptor 2 (TLR2)抑制剂。C29 阻断 hTLR2/1 和 hTLR2/6 信号，IC50值分别为 19.7 和 37.6 μM。
| 生物活性 | C29 is aToll-like receptor2 (TLR2)inhibitor. C29 blocks hTLR2/1 and hTLR2/6 signaling withIC50s of 19.7 and 37.6 μM, respectively[1]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | C29 (10 or 50 μΜ; 1 hour) blocks P3C- and P2C-induced IL-8 mRNA dose-dependently in HEK-TLR2 stable transfectants. C29 (50-200 μM; 1 hour) inhibits P3C- and P2C-induced IL-1β gene expression significantly at both 1 h and 4 h following stimulation in THP-1 cells[1].
C29 (25 or 50 μΜ; 1 hour) reduces P3C-induced but not P2C-induced TNF-α mRNA and IL-12 p40 protein significantly in primary murine macrophages[1].
C29 (50 μΜ; 1 hour) blocks TLR2 bacterial agonist-induced proinflammatory gene expression in HEK-TLR2 cells and murine macrophages[1].
Western Blot Analysis[1] | Cell Line: | THP-1 cells | | Concentration: | 150 μM | | Incubation Time: | 1 hours | | Result: | Diminished the interaction between endogenous TLR2 and myeloid differentiation primary response gene 88 (MyD88) at 15 and 30 min poststimulation with P3C. |
Western Blot Analysis[1] | Cell Line: | Murine peritoneal macrophages | | Concentration: | 50 μM | | Incubation Time: | 1 hours | | Result: | Blocked robust MAPK activation at 30 min and reduced NF-κB activation from 5 to 30 min.
Prevented P3C-induced degradation of IκBα at 15 and 30 min. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : ≥ 30 mg/mL(105.16 mM) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 3.5052 mL | 17.5260 mL | 35.0521 mL | | 5 mM | 0.7010 mL | 3.5052 mL | 7.0104 mL | | 10 mM | 0.3505 mL | 1.7526 mL | 3.5052 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (8.76 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (8.76 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
